Clinical Trials Logo

Delirium clinical trials

View clinical trials related to Delirium.

Filter by:

NCT ID: NCT06399679 Not yet recruiting - Clinical trials for Anticholinergic Toxicity

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

RIVA-AP
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.

NCT ID: NCT06394778 Not yet recruiting - Delirium Clinical Trials

Electroencephalogram Characteristics of Surgical Anesthetized Patients and Postoperative. Dilirium

Start date: April 22, 2024
Phase:
Study type: Observational

Purpose:Construct a perioperative EEG database for elderly patients under general anesthesia, and explore the correlation between their EEG spectrum characteristics and the occurrence and severity of postoperative delirium. Content:This study aims to investigate patients undergoing elective orthopedic surgery, analyze the changes in perioperative EEG spectrum, correlate with the occurrence and severity of POD, and explore the relationship between perioperative EEG changes and the development of postoperative delirium. Method: Patients aged over 60 years old who are scheduled for orthopedic surgery and plan to stay in hospital for more than two days were selected. All patients underwent preoperative MMSE and 3D-CAM assessments. Subsequently, anesthetic depth monitor electrodes were applied to the occipital or frontal-temporal regions of the patient to collect electroencephalograms of the occipital lobe during conscious and quiet states, the frontal lobe during general anesthesia, and the recovery room. During PACU, scores were calculated based on the CAM-ICU scale evaluation. During the first 5 days after surgery, patients were evaluated every day between 13:00 and 20:00 using 3D-CAM, or at any time when they showed obvious symptoms of delirium, unless they were discharged or taking sedatives (RASS < -3). Ten minutes after the end of the evaluation, patients' electroencephalograms were monitored in a conscious and quiet state, or in a state of obvious delirium. Patients were divided into a delirium group and a non-delirium group based on whether they developed delirium after surgery. The characteristics of electroencephalograms before, during, and after surgery were analyzed in both groups of patients.Research significance:The results of this study may provide objective indicators and theoretical basis for monitoring and diagnosing the occurrence and development of POD, which can help clinical doctors identify patients with increased delirium risk in the early stage, and adjust the plan in a timely manner to change the triggering risk factors of POD.

NCT ID: NCT06392308 Not yet recruiting - Clinical trials for Delirium, Postoperative

The Impact of Smoking on the Prognosis of Elderly Surgical Patients

Start date: September 1, 2024
Phase:
Study type: Observational

Postoperative delirium is a common complication that frequently occurs in elderly patients after surgery. It not only increases the length of hospital stays and healthcare costs but also raises the incidence of postoperative cognitive dysfunction and even mortality. However, the underlying mechanisms of its onset are not yet fully understood. Evidence suggests that smoking can lead to gut microbiota dysbiosis and metabolic dysfunction, and the gut microbiota and its metabolites play a crucial role in cognitive function through the gut-brain axis. Yet, no studies have reported whether smoking could affect the occurrence of postoperative delirium and the quality of postoperative recovery through the gut microbiota. This study aims to observe the incidence of postoperative delirium and the postoperative recovery quality scores between smokers and non-smokers.

NCT ID: NCT06382649 Not yet recruiting - Clinical trials for Anticholinergic Toxicity

Rivastigmine for Antimuscarinic Delirium

RIVA-AM
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production. Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.

NCT ID: NCT06361238 Not yet recruiting - Clinical trials for Delirium, Postoperative

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

Start date: April 30, 2024
Phase: Phase 3
Study type: Interventional

This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.

NCT ID: NCT06346990 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Effect of Listening to Holy Quran Recital on the Incidence of Delirium Post-CABG

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This study is planned to check the effect of holy Quran recital on the development of delirium after conronary artery bypass graft surgery (CABG). Different studies have been done before about the effects of non-pharmacological intervention on delirium after CABG, howvere, none was designed specifically to check the effect of Holy Qoyran on this outcome.

NCT ID: NCT06326424 Not yet recruiting - Dementia Clinical Trials

Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department

DELIRIUM
Start date: April 10, 2024
Phase:
Study type: Observational

Delirium is highly prevalent and very bad for patients with dementia. Delirium is a dangerous medical condition that occurs in 6-38% of older Emergency Department patients and 70% of ICU patients. A person who develops delirium in the ED or hospital has a 12 times higher odds of being newly diagnosed with dementia in the next year compared to a similar patient who does not become delirious. Delirium is especially dangerous for persons living with Alzheimer Disease and Related Dementias (AD/ADRD). Persons living with ADRD have an almost 50% chance of developing delirium in the hospital. Clinicians are bad at recognizing delirium. A recent systematic review led by the Geriatric Emergency Care Applied Research network (NIH funded) found that current delirium screening tools are at most 64% sensitive, meaning that physicians can identify some phenotypes of delirium well, but cannot easily rule out delirium in acutely ill older patients. The investigators propose integrating wrist biosensors into the emergency management of older adults with dementia. The investigators will monitor heart rate variability, movement, and electrodermal activity (electrical activity of at the level of the skin) to determine if an array of biosensors more sensitive to delirium than current verbal screening tools.

NCT ID: NCT06326372 Not yet recruiting - Hyperoxia Clinical Trials

The Effect of Intraoperative Hyperoxemia on Postoperative Delirium in Geriatric Patients

Start date: March 20, 2024
Phase:
Study type: Observational

Oxygen therapy is the most common treatment modality for patients with hypoxemia, but target values for normoxemia are not clearly defined. Therefore, iatrogenic hyperoxemia is a very common situation. Even though there are many side effects reported related to hyperoxemia and hyperoxemia is shown to be related to worse outcome than expected; clinicians still observe hyperoxemia frequently. Oxygen reserve index (ORi™) (Masimo Corp., Irvine, USA) can guide clinicians in detection of hyperoxia. ORi is a parameter which can evaluate partial pressure of oxygen (PaO2) rating from 0 to 1. There are growing evidences in ORi that it might be helpful to reduce hyperoxia in general anesthesia. Continuous ORi monitoring can be used for detecting and preventing hyperoxia. The ability to perform FiO2 titration with ORi may be an appropriate monitoring management to prevent the harmful effects of hyperoxia.In this study, in patients who underwent major abdominal surgery; It was aimed to investigate the effectiveness of ORi-guided FiO2 titration in preventing hyperoxia.

NCT ID: NCT06294158 Not yet recruiting - Critical Illness Clinical Trials

Light and Noise: Objectively Assessing Environmental Risk Factors for Delirium in the ICU

LANYARD-ICU
Start date: April 2024
Phase:
Study type: Observational

Recognition of delirium as a medical entity with relevance to both morbidity and mortality, especially in critically ill patients, is a relatively recent development. However, research into delirium prevention and treatment is now in focus of scientific efforts internationally. Knowledge of intensive care unit (ICU) environment as a potential modifiable risk factor for delirium is insufficient to this date. This study thus seeks to evaluate, whether potentially modifiable environmental factors, such as noise or dazzling, are associated with development of delirium. Knowledge derived from this investigation could change both the process of care provision in intensive care units as well as the design of ICUs in general in the future. This project is planned to be carried out as an observational pilot study at three perioperative ICUs at the University Medical Centre Graz. Adult patients shall be screened for inclusion, if not deeply sedated. Suitable patients shall be included into the study after written informed consent or deferred consent if they can be expected to remain in the ICU for at least another two days, if they are not already in delirium, if the ICU environment is not actively modified for therapeutic reasons and if no treatment limitations are in place. Over a study duration of one year, 250 to 300 patients are expected to be enrolled into the study. Of those, 60 to 120 patients are likely to develop delirium. Baseline data known to be of relevance for outcome prediction in critically ill patients and factors known to predispose for development of delirium during ICU and hospital stay will be collected. Study equipment will be deployed to measure noise levels and illumination repeatedly over the day. Daily assessments for delirium using the Confusion Assessment Method in Intensive Care Units (CAM-ICU) will be performed. Vital status, physiologic parameters and parameters of ongoing treatment will concomitantly be documented on a daily basis. Data on light and noise levels are then to be unified with parameters of physiology and treatment, vital status, and results of daily assessments for delirium. Statistical analysis using methods of descriptive and comparative statistics as well as both unadjusted and adjusted logistic regression analysis will be performed to identify factors significantly associated with the development of delirium (i.e., risk factors).

NCT ID: NCT06285721 Not yet recruiting - Delirium Clinical Trials

Delirium Treatment With Transcranial Electrical Stimulation

DELTES
Start date: February 26, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the effectiveness of standardized and personalized transcranial alternating current stimulation (tACS) in patients with postoperative delirium. To investigate this, will perform a double-blind, randomized, sham-controlled, multicenter trial. To test the safety and feasibility of tACS in delirious patients, the first 30 patients will be randomized to receive either active or sham tACS treatment in a 1:1 ratio through a pilot study. For the main phase of the study, patients will be randomized, resulting in an overall 1:1:1 allocation to standardized tACS, personalized tACS or sham treatment. Electroencephalogram (EEG) will be measured directly before and directly after the first stimulation session to assess whether tACS can reduce relative delta power. tACS or sham treatment will be given once daily for a maximum of 14 days, or until resolution of delirium or discharge (whichever comes first). During the treatment phase, presence and severity of delirium will be assessed daily. After the treatment phase, an additional EEG will be measured. Cognitive status will be assessed three months postoperative.